Prognostic Determinants in Prostate Cancer
暂无分享,去创建一个
Massimo Loda | M. Loda | R. DePinho | N. Martin | L. Mucci | Ronald A Depinho | Lorelei A Mucci | Neil E Martin
[1] A. Jemal,et al. Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.
[2] M. Desai,et al. Accuracy of the Kattan nomogram across prostate cancer risk‐groups , 2011, BJU international.
[3] T. Golub,et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[5] J. Cuzick,et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.
[6] Misop Han,et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.
[7] Gerald C. Chu,et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.
[8] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[9] Jonathan W. Pillow,et al. POSTER PRESENTATION Open Access , 2013 .
[10] M. Loda,et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Erik Holmberg,et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.
[12] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[13] Shuming Nie,et al. Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. , 2010, ACS nano.
[14] Mehmet Toner,et al. Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer , 2010, Science Translational Medicine.
[15] A. Ruffion,et al. Urinary prostate cancer 3 test: toward the age of reason? , 2010, Urology.
[16] C. Lawton,et al. Screening and Prostate-Cancer Mortality in a Randomized European Study , 2010 .
[17] R. DePinho,et al. Telomeres and telomerase in cancer. , 2010, Carcinogenesis.
[18] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[19] Stacey A. Kenfield,et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. DiPaola,et al. Contemporary risk profile of prostate cancer in the United States. , 2009, Journal of the National Cancer Institute.
[21] Andrew J Vickers,et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Haese*,et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[23] Jing Ma,et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Kantoff,et al. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. , 2009, Cancer research.
[25] H. Hricak,et al. Imaging , Diagnosis , Prognosis Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles , 2009 .
[26] L. Fink,et al. Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors , 2009, Cancer Epidemiology Biomarkers & Prevention.
[27] Hong Dai,et al. Imaging , Diagnosis , Prognosis Prognostic Value of Akt1 in Human Prostate Cancer : A Computerized Quantitative Assessment with Quantum Dot Technology , 2009 .
[28] J. Concato,et al. Molecular Markers and Death From Prostate Cancer , 2009, Annals of Internal Medicine.
[29] W. Hahn,et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. , 2009, Journal of the National Cancer Institute.
[30] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[31] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[32] Oscar Lin,et al. Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.
[33] W. Gerald,et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.
[34] Pierre I Karakiewicz,et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. , 2009, The Journal of urology.
[35] John T. Wei,et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.
[36] D. Dearnaley,et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] S. Srivastava,et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. , 2008, The Journal of urology.
[38] J. Köllermann,et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[40] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[41] B. Trask,et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.
[42] R. Babaian,et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. , 2008, The Journal of urology.
[43] Ruud H. Brakenhoff,et al. Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.
[44] J. Mosley,et al. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists , 2008, BMC Medical Genomics.
[45] Matthew Sydes,et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. , 2008, The Lancet. Oncology.
[46] S. Boorjian,et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. , 2008, The Journal of urology.
[47] Jianjun Yu,et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. , 2008, Cancer research.
[48] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[49] S. Digumarthy,et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.
[50] Glenn Heller,et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.
[51] A. Haese*,et al. Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.
[52] J. Witjes,et al. Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer , 2007, Clinical Cancer Research.
[53] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[54] S. Fosså,et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy , 2007, International Journal of Cancer.
[55] P. Lichter,et al. Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays , 2006, British Journal of Cancer.
[56] M. Mason,et al. The prognostic significance of perineural invasion in prostatic cancer biopsies , 2007, Cancer.
[57] Lei Wang,et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.
[58] Lennart Franzén,et al. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. , 2006, The Journal of urology.
[59] J. Weinstein,et al. Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.
[60] P. Scardino,et al. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). , 2005, Urology.
[61] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[62] James A Hanley,et al. Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.
[63] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[64] A. Renshaw,et al. Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .
[65] T. Thompson,et al. Erratum: High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence (Clinical Cancer Research (Octobet 1, 2004) 10 (6572-6578)) , 2005 .
[66] J. Manola,et al. Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone-Refractory Prostate Cancer Treated with Chemotherapy , 2005, Clinical Cancer Research.
[67] Robert A Gardiner,et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer , 2005, International journal of cancer.
[68] P. Walsh,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.
[69] N. Joste,et al. Association between cancer-free survival and telomere DNA content in prostate tumors. , 2005, The Journal of urology.
[70] Liang Cheng,et al. Perineural invasion in radical prostatectomy specimens: lack of prognostic significance. , 2004, The Journal of urology.
[71] Jaime Pujadas Oláno,et al. Natural history of early localized prostate cancer. , 2004, JAMA.
[72] P. Scardino,et al. High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence , 2004, Clinical Cancer Research.
[73] M. Hammond,et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] Alexandra L Hanlon,et al. Prostate cancer radiotherapy dose response: an update of the fox chase experience. , 2004, The Journal of urology.
[75] P. Scardino,et al. Expression of vascular endothelial growth factor receptor‐3 (VEGFR‐3) in human prostate , 2004, The Prostate.
[76] Gurkamal Chatta,et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy , 2003 .
[77] Michael W Kattan,et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] Ming-Hui Chen,et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.
[79] John T. Wei,et al. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions. , 2003, Urologic oncology.
[80] P. Walsh. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.
[81] O. Halvorsen,et al. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[82] M. Kattan,et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer , 2003, The Prostate.
[83] P. Abrahamsson,et al. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. , 2003, The Journal of urology.
[84] J Wade Harper,et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[85] S. Dhanasekaran,et al. The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.
[86] L. Kiemeney,et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.
[87] H. Frierson,et al. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years , 2002, Cancer.
[88] P. Kantoff,et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] M. Kattan,et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] E. Bergstralh,et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. , 2001, The Journal of urology.
[91] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[92] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[93] J. Serth,et al. Article no. bjoc.1999.0806 , 2022 .
[94] D. Bostwick,et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.
[95] M. Loda,et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.
[96] John T. Wei,et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. , 1999, The Journal of urology.
[97] A W Partin,et al. Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.
[98] M. Kattan,et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[99] C. Cordon-Cardo,et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[100] V. Kosma,et al. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer , 1999, The Prostate.
[101] S B Malkowicz,et al. Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .
[102] A. Borkowski,et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. , 1998, Urology.
[103] Pär Stattin,et al. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer , 1998, The Prostate.
[104] M. Kattan,et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.
[105] M. Banerjee,et al. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] A. Nagafuchi,et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. , 1997, Cancer research.
[107] F. Mostofi,et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. , 1996, The Journal of urology.
[108] J W Moul,et al. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.
[109] J. Moul,et al. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[110] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[111] F. Marshall,et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.
[112] J W Moul,et al. Infrequent RAS oncogene mutations in human prostate cancer , 1992, The Prostate.
[113] T. Stamey,et al. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. , 1989, The Journal of urology.
[114] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.